LONG-TIME INCUBATION OF MONOCYTIC U-937 CELLS WITH LDL INCREASES SPECIFIC PAF-ACETHER BINDING AND THE CELLULAR ACETYLHYDROLASE ACTIVITY

被引:14
作者
KORTH, R
MIDDEKE, M
机构
[1] UNIV MUNICH,MED POLIKLIN,PETTENKOFERSTR 8A,W-8000 MUNICH,GERMANY
[2] KREISLAUFKRANKHEITEN,INST PROPHYLAXE & EPIDEMIOL,MUNICH,GERMANY
关键词
PAF-ACETHER RECEPTORS; PAF ANTAGONISTS; ACETYLHYDROLASE; PROTEIN KINASE-C; MONOCYTES; LOW DENSITY LIPOPROTEINS;
D O I
10.1016/0009-3084(91)90020-C
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Besides the well established role of low density lipoproteins (LDL), the phospholipid PAF-acether (paf) seems to be involved in atherogenesis. The effect of LDL (10-mu-g/ml for 24 h, n = 3) on paf binding characteristics of monocyte/macrophage-like U 937 cells was investigated using the radioligand [H-3]paf, unlabeled paf and the paf receptor antagonist WEB 2086. The specific [H-3]paf binding significantly increased at 1.4 nM (P < 0.02) and 2.8 nM (P < 0.01) added [H-3]paf with an increased number of paf binding sites in the Scatchard plot analysis of the data. Specific paf binding was functionally active since paf mediated a cellular [Ca2+]i rise. The protein kinase C (PKC) activator PMA (1 nM, 37-degrees-C) expressed specific [H-3]paf binding already after a 15-min incubation period, indicating a PKC activation as the decisive step of paf receptor expression. LDL also stimulated the paf degrading cellular acetylhydrolase significantly by increasing both K(m) (9.4 +/- 1.9 vs. 2.0 +/- 0.5-mu-M, P < 0.02) and nu-max (0.5 +/- 0.2 vs. 0.2 +/- 0.0 nmol/min per mg cell protein, P < 0.02). The data demonstrate that LDL increases the number of paf receptors on monocyte/macrophage-like U 937 cells and interferes with the dynamics and/or synthesis of the cellular acetyl hydrolase. These effects could be of importance in the pathogenesis of atherosclerosis.
引用
收藏
页码:207 / 213
页数:7
相关论文
共 30 条
[1]   1,25-(OH)2 VITAMIN-D-3 ENHANCES PAF-STIMULATED CALCIUM MOBILIZATION IN U937 CELLS BY EXPRESSION OF SPECIFIC PAF BINDING-SITES [J].
AEPFELBACHER, M ;
KORTH, R ;
WEBER, PC .
BIOCHIMICA ET BIOPHYSICA ACTA, 1990, 1051 (02) :179-184
[2]  
BARZAGHI G, 1989, J PHARMACOL EXP THER, V248, P559
[3]  
BENVENISTE J, 1979, CR ACAD SCI D NAT, V289, P1037
[4]  
Benveniste J, 1988, Prog Clin Biol Res, V282, P73
[5]   LEUKOCYTE-DEPENDENT HISTAMINE-RELEASE FROM RABBIT PLATELETS - ROLE OF IGE, BASOPHILS, AND A PLATELET-ACTIVATING FACTOR [J].
BENVENISTE, J ;
HENSON, PM ;
COCHRANE, CG .
JOURNAL OF EXPERIMENTAL MEDICINE, 1972, 136 (06) :1356-+
[6]   TRIAZOLODIAZEPINES - DISSOCIATION OF THEIR PAF (PLATELET-ACTIVATING-FACTOR) ANTAGONISTIC AND CNS ACTIVITY [J].
CASALSSTENZEL, J ;
WEBER, KH .
BRITISH JOURNAL OF PHARMACOLOGY, 1987, 90 (01) :139-146
[7]  
DEMOPOULOS CA, 1979, J BIOL CHEM, V254, P9355
[8]   PROTECTIVE EFFECT OF BN-52021, A SPECIFIC ANTAGONIST OF PLATELET-ACTIVATING FACTOR (PAF-ACETHER) AGAINST DIET-INDUCED CHOLESTERYL ESTER DEPOSITION IN RABBIT AORTA [J].
FELISTE, R ;
PERRET, B ;
BRAQUET, P ;
CHAP, H .
ATHEROSCLEROSIS, 1989, 78 (2-3) :151-158
[9]  
GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151
[10]   BINDING-SITE ON MACROPHAGES THAT MEDIATES UPTAKE AND DEGRADATION OF ACETYLATED LOW-DENSITY LIPOPROTEIN, PRODUCING MASSIVE CHOLESTEROL DEPOSITION [J].
GOLDSTEIN, JL ;
HO, YK ;
BASU, SK ;
BROWN, MS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1979, 76 (01) :333-337